Balance Sheet Sarepta Therapeutics, Inc.

Stocks

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 22/07/2026 am IST			5-day change	1st Jan Change
16.21 ^USD	-3.68%		-9.74%	-24.67%

30/06	Sarepta Therapeutics Announces FDA Acceptance Of Supplemental New Drug Applications For Amondys 45 And Vyondys 53 For Duchenne Muscular Dystrophy	CI
30/06	Sarepta Therapeutics Gets FDA Review for Duchenne Muscular Dystrophy Applications	MT

9da71b8db74d6560b.sH03e58bepGep5_qNOXG9F11zvDlTjrZHInndvoHukw.ghh0JP50AsWn5P6LfYOchT8AvbauHlCKb-KsO5VG1S3vFnEO_mhO3PnO-A

Published financial data: SAREPTA THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	70Cr	93Cr	124.33Cr	190.2Cr	219.82Cr
Total Revenues	70Cr	93Cr	124.33Cr	190.2Cr	219.82Cr
Cost of Goods Sold, Total	87Cr	101.11Cr	102.77Cr	112.36Cr	236.17Cr
Gross Profit	-17Cr	-7.81Cr	22Cr	78Cr	-16Cr
Selling General & Admin Expenses, Total	28Cr	45Cr	48Cr	56Cr	49Cr
Amortization of Goodwill and Intangible Assets - (IS)	7L	7L	15.59L	24.05L	26.22L
Other Operating Expenses, Total	28Cr	45Cr	48Cr	56Cr	49Cr
Operating Income	-45Cr	-53Cr	-27Cr	22Cr	-66Cr
Interest Expense, Total	-6.35Cr	-5.32Cr	-2.2Cr	-1.84Cr	-3.81Cr
Interest And Investment Income	4L	1.65Cr	3.63Cr	3.06Cr	3.08Cr
Net Interest Expenses	-6.32Cr	-3.68Cr	1.42Cr	1.22Cr	-73.77L
Other Non Operating Income (Expenses)	-9L	-69.21L	6L	-28.45L	-19.42L
EBT, Excl. Unusual Items	-51Cr	-57Cr	-25Cr	23Cr	-67Cr
Restructuring Charges	-	-	-	-	-4.2Cr
Gain (Loss) On Sale Of Investments	-43.31L	86.6L	1.94Cr	4.11Cr	-99.87L
Gain (Loss) On Sale Of Assets	10Cr	-	10Cr	-	-
Asset Writedown	-5L	-60L	-	-	-
In Process R&D Expenses	-	-	-	-	-
Legal Settlements	-	-	-	-	-
Other Unusual Items	-28L	-12Cr	-39Cr	-78.38L	1.69Cr
EBT, Incl. Unusual Items	-42Cr	-69Cr	-52Cr	26Cr	-70Cr
Income Tax Expense	-2L	1.35Cr	1.59Cr	2.55Cr	1.12Cr
Earnings From Continuing Operations	-42Cr	-70Cr	-54Cr	24Cr	-71Cr
Net Income to Company	-42Cr	-70Cr	-54Cr	24Cr	-71Cr
Net Income - (IS)	-42Cr	-70Cr	-54Cr	24Cr	-71Cr
Net Income to Common Incl Extra Items	-42Cr	-70Cr	-54Cr	24Cr	-71Cr
Net Income to Common Excl. Extra Items	-42Cr	-70Cr	-54Cr	24Cr	-71Cr
Per Share Items
Net EPS - Basic	-5.15	-8.03	-5.8	2.47	-7.13
Basic EPS - Continuing Operations	-5.15	-8.03	-5.8	2.47	-7.13
Basic Weighted Average Shares Outstanding	8.13Cr	8.76Cr	9.24Cr	9.51Cr	10Cr
Net EPS - Diluted	-5.15	-8.03	-5.8	2.34	-7.13
Diluted EPS - Continuing Operations	-5.15	-8.03	-5.8	2.34	-7.13
Diluted Weighted Average Shares Outstanding	8.13Cr	8.76Cr	9.24Cr	11Cr	10Cr
Normalized Basic EPS	-3.95	-4.1	-1.71	1.5	-4.16
Normalized Diluted EPS	-3.95	-4.1	-1.71	1.32	-4.16
Supplemental Items
EBITDA	-41Cr	-49Cr	-22Cr	26Cr	-61Cr
EBITA	-45Cr	-53Cr	-27Cr	22Cr	-65Cr
EBIT	-45Cr	-53Cr	-27Cr	22Cr	-66Cr
EBITDAR	-36Cr	-43Cr	-16Cr	36Cr	-47Cr
Total Revenues (As Reported)	70Cr	93Cr	124.33Cr	190.2Cr	219.82Cr
Effective Tax Rate - (Ratio)	0.04	-1.96	-3.05	9.79	-1.59
Current Domestic Taxes	-40T	1.32Cr	1.53Cr	2.48Cr	1.02Cr
Current Foreign Taxes	2L	9L	8L	10L	13.78L
Total Current Taxes	1L	1.41Cr	1.6Cr	2.58Cr	1.15Cr
Deferred Domestic Taxes	-	-	-	-	-
Deferred Foreign Taxes	-3L	-6L	-2L	-2L	-4L
Total Deferred Taxes	-3L	-6L	-2L	-2L	-4L
Normalized Net Income	-32Cr	-36Cr	-16Cr	14Cr	-42Cr
Interest on Long-Term Debt	6.35Cr	5.32Cr	2.2Cr	1.84Cr	3.48Cr
Supplemental Operating Expense Items
Advertising Expense	-	-	2.86Cr	3.2Cr	2.95Cr
Selling and Marketing Expenses	-	-	2.86Cr	3.2Cr	2.95Cr
Research And Development Expense From Footnotes	77Cr	88Cr	88Cr	80Cr	152.21Cr
Net Rental Expense, Total	4.75Cr	5.37Cr	6.83Cr	10Cr	15Cr
Imputed Operating Lease Interest Expense	2.17Cr	1.66Cr	79.84L	1.12Cr	3.77Cr
Imputed Operating Lease Depreciation	2.58Cr	3.71Cr	6.04Cr	9.24Cr	11Cr
Stock-Based Comp., COGS (Total)	5.05Cr	6.13Cr	8.25Cr	7.4Cr	4.74Cr
Stock-Based Comp., SG&A Exp. (Total)	6.34Cr	17Cr	10Cr	11Cr	7.6Cr
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	11Cr	23Cr	18Cr	18Cr	12Cr

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	211.59Cr	97Cr	43Cr	110.3Cr	80Cr
Short Term Investments	-	102.26Cr	124.78Cr	25Cr	14Cr
Total Cash And Short Term Investments	211.59Cr	198.94Cr	167.62Cr	135.48Cr	94Cr
Accounts Receivable, Total	17Cr	26Cr	43Cr	64Cr	50Cr
Other Receivables	-	33.11L	95.93L	1.31Cr	1.73Cr
Total Receivables	17Cr	26Cr	44Cr	65Cr	52Cr
Inventory	19Cr	20Cr	32Cr	75Cr	91Cr
Prepaid Expenses	2.95Cr	2.96Cr	3.02Cr	3.07Cr	2.92Cr
Other Current Assets, Total	10Cr	7.52Cr	11Cr	29Cr	13Cr
Total Current Assets	260.41Cr	255.79Cr	257.93Cr	307.35Cr	253.79Cr
Gross Property Plant And Equipment	35Cr	39Cr	55Cr	72Cr	75Cr
Accumulated Depreciation	-11Cr	-15Cr	-19Cr	-23Cr	-28Cr
Net Property Plant And Equipment	24Cr	24Cr	36Cr	49Cr	47Cr
Long-term Investments	3.49Cr	3.13Cr	65.27L	14Cr	1.06Cr
Other Intangibles, Total	1.42Cr	75.78L	2.96Cr	2.69Cr	2.89Cr
Deferred Tax Assets Long-Term	-	-	-	-	28.22L
Other Long-Term Assets, Total	26Cr	29Cr	29Cr	24Cr	30Cr
Total Assets	314.8Cr	312.84Cr	326.46Cr	396.32Cr	334.97Cr
Liabilities
Accounts Payable, Total	7.67Cr	9.59Cr	16Cr	21Cr	28Cr
Accrued Expenses, Total	21Cr	34Cr	20Cr	24Cr	24Cr
Current Portion of Long-Term Debt	-	-	11Cr	-	-
Current Portion of Leases	1.5Cr	1.55Cr	1.78Cr	1.33Cr	1.12Cr
Current Income Taxes Payable	-	1.25Cr	1.38Cr	1.74Cr	47.55L
Unearned Revenue Current, Total	8.92Cr	8.92Cr	5.04Cr	13Cr	44Cr
Other Current Liabilities	6.5Cr	7.08Cr	10Cr	11Cr	12Cr
Total Current Liabilities	45Cr	62Cr	65Cr	73Cr	109.53Cr
Long-Term Debt	109.69Cr	154.43Cr	113.25Cr	113.71Cr	83Cr
Long-Term Leases	4.15Cr	5.76Cr	14Cr	19Cr	20Cr
Unearned Revenue Non Current	57Cr	48Cr	44Cr	32Cr	8.39Cr
Other Non Current Liabilities	5.46Cr	3.69Cr	4.11Cr	4.92Cr	15.29L
Total Liabilities	222Cr	274.34Cr	240.52Cr	243.54Cr	220.91Cr
Common Stock, Total	9T	9T	9T	10T	11T
Additional Paid In Capital	413.48Cr	429.68Cr	530.46Cr	573.89Cr	604.26Cr
Retained Earnings	-320.67Cr	-391.02Cr	-444.62Cr	-421.1Cr	-487.7Cr
Treasury Stock	-	-	-	-	-2.53Cr
Comprehensive Income and Other	-20T	-16.64L	9L	-2L	3L
Total Common Equity	93Cr	38Cr	86Cr	152.77Cr	114.06Cr
Total Equity	93Cr	38Cr	86Cr	152.77Cr	114.06Cr
Total Liabilities And Equity	314.8Cr	312.84Cr	326.46Cr	396.32Cr	334.97Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	8.71Cr	8.8Cr	9.39Cr	9.7Cr	10Cr
ECS Total Common Shares Outstanding	8.71Cr	8.8Cr	9.37Cr	9.69Cr	10Cr
Book Value / Share	10.65	4.38	9.17	15.77	10.87
Tangible Book Value	91Cr	38Cr	83Cr	150.09Cr	111.17Cr
Tangible Book Value Per Share	10.49	4.29	8.85	15.49	10.59
Total Debt	115.34Cr	161.74Cr	139.68Cr	134.29Cr	103.95Cr
Net Debt	-96Cr	-37Cr	-28Cr	-1.19Cr	9.99Cr
Debt Equivalent Oper. Leases	38Cr	43Cr	55Cr	83Cr	117.11Cr
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	-	-	-	-	-
Inventories - Work In Process, Total	-	-	-	-	-
Inventories - Finished Goods, Total	-	-	-	-	-
Land - (BS)	51.83L	51.83L	51.83L	1.02Cr	1.02Cr
Buildings, Total	4.76Cr	4.79Cr	4.81Cr	5.12Cr	5.22Cr
Machinery, Total	7.5Cr	10Cr	12Cr	14Cr	15Cr
Full Time Employees	840	1.16T	1.31T	1.37T	835

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-42Cr	-70Cr	-54Cr	24Cr	-71Cr
Depreciation & Amortization - CF	3.66Cr	4Cr	4.25Cr	3.5Cr	4.15Cr
Amortization of Goodwill and Intangible Assets - (CF)	13.06L	18.14L	19L	27L	30L
Depreciation & Amortization, Total	3.79Cr	4.18Cr	4.44Cr	3.77Cr	4.45Cr
Amortization of Deferred Charges, Total - (CF)	1L	50T	-	-	-
(Gain) Loss From Sale Of Asset	-10Cr	1.08Cr	-10Cr	-	-
(Gain) Loss on Sale of Investments - (CF)	44.88L	25.75L	-1.59Cr	-4.03Cr	1.2Cr
Asset Writedown & Restructuring Costs	-	-	-	-	-
Stock-Based Compensation (CF)	11Cr	23Cr	18Cr	18Cr	12Cr
Other Operating Activities, Total	1.93Cr	13Cr	41Cr	9.38Cr	25Cr
Change In Accounts Receivable	-5.16Cr	-6.16Cr	-19Cr	-20Cr	20Cr
Change In Inventories	-8.38Cr	-5.08Cr	-15Cr	-40Cr	-30Cr
Change In Accounts Payable	2.33Cr	15Cr	-5.01Cr	11Cr	10Cr
Change in Unearned Revenues	-8.92Cr	-8.92Cr	-8.68Cr	-3.22Cr	7.21Cr
Change in Other Net Operating Assets	10Cr	1.46Cr	-1.07Cr	-20Cr	-9L
Cash from Operations	-44Cr	-33Cr	-50Cr	-21Cr	-21Cr
Capital Expenditure	-3.85Cr	-3.08Cr	-7.61Cr	-14Cr	-10Cr
Cash Acquisitions	-	-	-	-	-
Sale (Purchase) of Intangible assets	10Cr	-	9.08Cr	-1Cr	-78.76L
Investment in Marketable and Equity Securities, Total	44Cr	-101.36Cr	-18Cr	90Cr	18Cr
Other Investing Activities, Total	-41.09L	-24.27L	-	-	-
Cash from Investing	50Cr	-104.69Cr	-17Cr	76Cr	6.96Cr
Long-Term Debt Issued, Total	-	112.74Cr	-	-	-
Total Debt Issued	-	112.74Cr	-	-	-
Long-Term Debt Repaid, Total	-	-82Cr	-	-68T	-16Cr
Total Debt Repaid	-	-82Cr	-	-68T	-16Cr
Issuance of Common Stock	57Cr	3Cr	5.12Cr	7.95Cr	3.87Cr
Repurchase of Common Stock	-77.65L	-	-	-	-2.5Cr
Other Financing Activities, Total	-	-10Cr	7.38Cr	4.53Cr	-1.94Cr
Cash from Financing	56Cr	23Cr	13Cr	12Cr	-17Cr
Net Change in Cash	61Cr	-113.97Cr	-54Cr	67Cr	-30Cr
Supplemental Items
Cash Interest Paid	5.59Cr	4.44Cr	1.59Cr	1.59Cr	1.49Cr
Cash Income Tax Paid (Refund)	6L	16.95L	1.51Cr	2.26Cr	3.76Cr
Levered Free Cash Flow	-2.49Cr	-4.95Cr	-35Cr	-45Cr	9.59Cr
Unlevered Free Cash Flow	1.48Cr	-1.62Cr	-33Cr	-43Cr	12Cr
Change In Net Working Capital	-8.01Cr	-7.11Cr	41Cr	65Cr	-47Cr
Net Debt Issued / Repaid	-	30Cr	-	-68T	-16Cr

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-9.16	-10.56	-5.24	3.77	-11.24
Return on Total Capital	-14.34	-16.29	-7.86	5.34	-16.32
Return On Equity %	-49.57	-107.16	-86.15	19.71	-53.47
Return on Common Equity	-49.57	-107.16	-86.15	19.71	-53.47
Margin Analysis
Gross Profit Margin %	-23.63	-8.37	17.34	40.92	-7.43
SG&A Margin	40.27	48.38	38.76	29.33	22.37
EBITDA Margin %	-58.6	-52.35	-17.97	13.45	-27.9
EBITA Margin %	-63.81	-56.63	-21.39	11.61	-29.79
EBIT Margin %	-64	-56.83	-21.54	11.47	-29.92
Income From Continuing Operations Margin %	-59.66	-75.4	-43.11	12.37	-32.45
Net Income Margin %	-59.66	-75.4	-43.11	12.37	-32.45
Net Avail. For Common Margin %	-59.66	-75.4	-43.11	12.37	-32.45
Normalized Net Income Margin	-45.71	-38.44	-12.72	7.48	-18.97
Levered Free Cash Flow Margin	-3.55	-5.3	-27.99	-23.42	4.36
Unlevered Free Cash Flow Margin	2.1	-1.74	-26.88	-22.82	5.45
Asset Turnover
Asset Turnover	0.23	0.3	0.39	0.53	0.6
Fixed Assets Turnover	2.71	3.87	4.13	4.5	4.58
Receivables Turnover (Average Receivables)	4.57	4.36	3.62	3.57	3.86
Inventory Turnover (Average Inventory)	4.15	5.18	3.9	2.09	2.84
Short Term Liquidity
Current Ratio	5.75	4.13	3.95	4.2	2.32
Quick Ratio	5.05	3.63	3.24	2.74	1.33
Operating Cash Flow to Current Liabilities	-0.98	-0.53	-0.77	-0.28	-0.19
Days Sales Outstanding (Average Receivables)	79.87	83.72	100.77	102.63	94.56
Days Outstanding Inventory (Average Inventory)	87.95	70.43	93.55	174.73	128.64
Average Days Payable Outstanding	41.7	30.62	41.51	44.77	35.78
Cash Conversion Cycle (Average Days)	126.11	123.53	152.81	232.59	187.42
Long Term Solvency
Total Debt/Equity	124.29	420.15	162.54	87.9	91.14
Total Debt / Total Capital	55.42	80.77	61.91	46.78	47.68
LT Debt/Equity	122.67	416.12	148.19	87.03	90.16
Long-Term Debt / Total Capital	54.69	80	56.44	46.32	47.17
Total Liabilities / Total Assets	70.52	87.69	73.68	61.45	65.95
EBIT / Interest Expense	-7.07	-9.96	-12.17	11.86	-17.25
EBITDA / Interest Expense	-5.73	-8.16	-7.05	19.54	-12.24
(EBITDA - Capex) / Interest Expense	-6.33	-8.74	-10.5	12.1	-14.91
Total Debt / EBITDA	-3.17	-3.72	-9.01	3.74	-2.23
Net Debt / EBITDA	2.65	0.86	1.8	-0.03	-0.21
Total Debt / (EBITDA - Capex)	-2.87	-3.47	-6.04	6.04	-1.83
Net Debt / (EBITDA - Capex)	2.39	0.8	1.21	-0.05	-0.18
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	29.96	32.93	33.26	52.97	15.58
Gross Profit, 1 Yr. Growth %	-32.45	-52.93	-356.47	261.01	-121
EBITDA, 1 Yr. Growth %	-23.49	18.74	-54.8	-214.49	-339.73
EBITA, 1 Yr. Growth %	-20.42	17.97	-50.23	-183.02	-396.57
EBIT, 1 Yr. Growth %	-20.36	18.03	-50.05	-181.43	-401.62
Earnings From Cont. Operations, 1 Yr. Growth %	-24.43	67.98	-23.81	-143.89	-403.27
Net Income, 1 Yr. Growth %	-24.43	67.98	-23.81	-143.89	-403.27
Normalized Net Income, 1 Yr. Growth %	-17.28	11.8	-56.38	-189.93	-389.71
Diluted EPS Before Extra, 1 Yr. Growth %	-27.52	55.9	-27.8	-140.31	-404.57
Accounts Receivable, 1 Yr. Growth %	26.65	49.38	67.76	48.01	-21.09
Inventory, 1 Yr. Growth %	-19.72	9.54	58.29	132.29	21.97
Net Property, Plant and Equip., 1 Yr. Growth %	-16.13	3.51	45.76	36.84	-3.69
Total Assets, 1 Yr. Growth %	5.47	-0.62	4.35	21.4	-15.48
Tangible Book Value, 1 Yr. Growth %	22.14	-58.7	119.87	80.89	-25.93
Common Equity, 1 Yr. Growth %	21.82	-58.52	123.23	77.78	-25.34
Cash From Operations, 1 Yr. Growth %	-512.38	-26.59	53.99	-58.92	-0.15
Capital Expenditures, 1 Yr. Growth %	-53.18	-19.92	146.9	79.95	-25.54
Levered Free Cash Flow, 1 Yr. Growth %	-91.11	400.36	536.71	34.95	-122.19
Unlevered Free Cash Flow, 1 Yr. Growth %	-106.08	-154.31	1.46T	37.18	-128.46
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	35.76	31.43	33.09	42.78	32.97
Gross Profit, 2 Yr. CAGR %	-16.25	-43.61	16	204.28	-12.94
EBITDA, 2 Yr. CAGR %	-9.13	-4.69	-25.78	-28.06	65.67
EBITA, 2 Yr. CAGR %	-7.27	-3.11	-22.45	-35.72	56.92
EBIT, 2 Yr. CAGR %	-7.24	-3.05	-22.3	-36.23	56.72
Earnings From Cont. Operations, 2 Yr. CAGR %	-23.47	12.67	13.13	-42.17	15.37
Net Income, 2 Yr. CAGR %	-23.47	12.67	13.13	-42.17	15.37
Normalized Net Income, 2 Yr. CAGR %	-3.02	-3.83	-29.41	-37.37	61.9
Diluted EPS Before Extra, 2 Yr. CAGR %	-27.16	6.3	6.09	-46.05	10.87
Accounts Receivable, 2 Yr. CAGR %	37.43	37.54	58.3	57.57	8.07
Inventory, 2 Yr. CAGR %	4.24	-6.23	31.67	91.75	68.32
Net Property, Plant and Equip., 2 Yr. CAGR %	18.85	-6.82	22.83	41.23	14.8
Total Assets, 2 Yr. CAGR %	31.41	2.38	1.84	12.55	1.3
Tangible Book Value, 2 Yr. CAGR %	6.5	-28.98	-4.71	99.43	15.75
Common Equity, 2 Yr. CAGR %	6.5	-28.91	-3.77	99.22	15.21
Cash From Operations, 2 Yr. CAGR %	-1.47	74	6.32	-20.47	-35.96
Capital Expenditures, 2 Yr. CAGR %	-19.66	-38.76	40.62	110.79	15.75
Levered Free Cash Flow, 2 Yr. CAGR %	-71.3	-57.99	532.55	185.51	-46.1
Unlevered Free Cash Flow, 2 Yr. CAGR %	-77.18	-74.18	228.3	350.65	-38.47
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	32.6	34.81	32.04	39.42	33.06
Gross Profit, 3 Yr. CAGR %	7.13	-30.89	-4.24	69.36	24.81
EBITDA, 3 Yr. CAGR %	7.42	-0.65	-25.37	-14.24	7.45
EBITA, 3 Yr. CAGR %	9.41	0.48	-22.11	-20.67	7.01
EBIT, 3 Yr. CAGR %	9.35	0.51	-21.99	-21.08	7.05
Earnings From Cont. Operations, 3 Yr. CAGR %	4.98	-0.54	-1.1	-17.49	0.47
Net Income, 3 Yr. CAGR %	4.98	-0.54	-1.1	-17.49	0.47
Normalized Net Income, 3 Yr. CAGR %	11.42	1.69	-25.85	-23.48	4.78
Diluted EPS Before Extra, 3 Yr. CAGR %	-1.93	-6.13	-6.56	-23.16	-3.9
Accounts Receivable, 3 Yr. CAGR %	51.82	41.3	46.96	54.79	25.13
Inventory, 3 Yr. CAGR %	14.07	5.97	11.65	59.1	64.91
Net Property, Plant and Equip., 3 Yr. CAGR %	34.62	13.5	8.16	27.33	24.31
Total Assets, 3 Yr. CAGR %	24.23	19.73	3.03	7.98	2.3
Tangible Book Value, 3 Yr. CAGR %	-3.62	-22.34	3.51	17.99	43.35
Common Equity, 3 Yr. CAGR %	-3.49	-22.22	4.1	18.08	43.63
Cash From Operations, 3 Yr. CAGR %	4.47	-10.67	67.05	-22.56	-14.2
Capital Expenditures, 3 Yr. CAGR %	-14.3	-19.74	-2.54	52.67	49
Levered Free Cash Flow, 3 Yr. CAGR %	-53.36	-45.33	7.47	271.39	20.62
Unlevered Free Cash Flow, 3 Yr. CAGR %	-59.64	-61.5	11.22	140.99	77.62
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	164.51	43.27	32.8	37.94	32.41
Gross Profit, 5 Yr. CAGR %	-1.69	-11.92	9.83	26.91	-7.82
EBITDA, 5 Yr. CAGR %	9.93	29.41	-7.61	-12.48	2.67
EBITA, 5 Yr. CAGR %	11.39	30.25	-4.91	-15.77	3.07
EBIT, 5 Yr. CAGR %	11.4	30.03	-4.86	-16.02	3.12
Earnings From Cont. Operations, 5 Yr. CAGR %	9.4	69.23	8.17	-19.94	5.18
Net Income, 5 Yr. CAGR %	9.4	69.23	8.17	-19.94	5.18
Normalized Net Income, 5 Yr. CAGR %	14.37	31.49	-7.38	-16.06	1.46
Diluted EPS Before Extra, 5 Yr. CAGR %	-1.26	56.28	1.21	-24.79	0.06
Accounts Receivable, 5 Yr. CAGR %	101.03	54.14	54.38	47.6	29.96
Inventory, 5 Yr. CAGR %	70.79	19.53	20.81	34.34	31.58
Net Property, Plant and Equip., 5 Yr. CAGR %	44.32	41.52	29.77	23.87	10.77
Total Assets, 5 Yr. CAGR %	49.32	19.05	14.73	16.8	2.33
Tangible Book Value, 5 Yr. CAGR %	22.7	-13.4	-4.06	13.25	8.24
Common Equity, 5 Yr. CAGR %	22.48	-13.38	-3.6	13.3	8.41
Cash From Operations, 5 Yr. CAGR %	12.51	7	5.21	-14.73	13.84
Capital Expenditures, 5 Yr. CAGR %	48.44	20.77	4.47	18.09	4.4
Levered Free Cash Flow, 5 Yr. CAGR %	-29.99	12.44	7.21	8.02	-19.31
Unlevered Free Cash Flow, 5 Yr. CAGR %	-36.85	-7.49	8.27	8.88	-13.19